Trials / Terminated
TerminatedNCT01731990
Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Effects on Arterial Structure and Function of ACZ885 in Patients With Intermittent Claudication.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on the leg artery structure and physical activity in patients with atherosclerotic peripheral artery disease and leg pain from walking.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canakinumab (ACZ885) | Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use. |
| DRUG | Placebo | Matching placebo of Canakinumab |
Timeline
- Start date
- 2012-10-30
- Primary completion
- 2016-08-04
- Completion
- 2016-08-04
- First posted
- 2012-11-22
- Last updated
- 2025-04-29
- Results posted
- 2017-08-22
Locations
14 sites across 3 countries: United States, Germany, Jordan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01731990. Inclusion in this directory is not an endorsement.